Abstract

Cistanche deserticola Ma, commonly known as desert‑living cistanche, is a rare tonic herb endemic to arid zones of China, nicknamed "desert ginseng" in traditional ethnopharmacology. Its succulent scaly stem serves as official medicinal material, rich in phenylethanoid glycosides (PhGs), iridoids, lignans, polysaccharides and dozens of secondary metabolites. Cumulative pharmacological evidence highlights its bioactivities including neuroprotection, cardioprotection, reproductive regulation, bone‑metabolism modulation, intestinal homeostasis improvement and bidirectional immunomodulation. In 2023, Chinese national health authorities officially included Cistanche deserticola into the Food‑Medicine Homology inventory, unlocking legal access for ordinary‑food and nutraceutical manufacturing. The whole industrial scale has exceeded 20 billion RMB, creating combined ecological, social and economic value. Nevertheless, large‑scale food transformation still confronts multiple bottlenecks such as parasitic‑cultivation limitations, inconsistent quality control systems, product homogenization and insufficient global regulatory recognition. This review reorganizes botanical traits, core bioactive constituents, multi‑target pharmacological mechanisms, domestic‑overseas food‑development status, major industrial challenges and actionable countermeasures. It aims to provide structured theoretical references for nutraceutical R&D, market promotion and sustainable industrial conversion from raw‑material resource to high‑value consumer goods.

Keywords: Cistanche deserticola; phenylethanoid glycosides; food‑medicine homology; pharmacological mechanism; functional‑food development; industrial challenge

1. Introduction

The global consumer demand for plant‑derived preventive nutrition and natural functional ingredients keeps expanding over recent decades. Herbs with long‑standing traditional usage and modern experimental validation attract extensive attention from functional‑food and dietary‑supplement industries. Among Traditional Chinese Medicine (TCM) botanicals, Cistanche deserticola represents a typical desert‑origin holistic tonic resource. As an obligate holoparasite without chlorophyll, it completes its life cycle by attaching to root systems of host plants Haloxylon ammodendron. Historical TCM classics such as Xin Xiu Ben Cao and Shen Nong Ben Cao Jing documented its therapeutic effects for physical exhaustion, internal deficiency, gynecological disorders, lumbago and senile constipation.

For decades, Cistanche deserticola was only permitted for pharmaceutical and healthcare‑food applications. The policy milestone arrived in 2023: China's National Health Commission approved desert cistanche as new Food‑Medicine Homology material, permitting formulation within conventional food products. This regulatory shift opens enormous market space beyond prescription drugs and recorded health foods. According to industrial statistics, cumulative planting area across Inner Mongolia, Xinjiang and Gansu has reached more than 6 million mu; annual dried raw‑herb output surpasses 7 000 tons, with Xinjiang contributing roughly 80 % of national raw‑material supply. Total market size covering crude drug, decoction pieces, proprietary Chinese patent medicines and health‑related consumer goods approximates 20.6 billion RMB.

Even with promising resource endowments, translating laboratory pharmacological findings into market‑ready food commodities meets real‑world obstacles. Parasitic‑plant cultivation suffers low seed‑germination and host‑attachment efficiency. Harvesting, drying and storage readily trigger browning, mildew and loss of signature PhGs markers. Fragmented local standards differ across producing provinces, while counterfeit and adulterated incidents occur in circulation channels. Most commercially available goods remain low‑value primary processed slices, whereas innovative consumer‑oriented food formats are still limited. Outside China, safety‑assessment barriers slow down international food‑ingredient authorization.

This paper synthesizes published phytochemical investigations, pre‑clinical mechanism studies, limited human clinical observations and industrial survey data. It systematically sorts botanical features, representative bioactive compounds, multi‑organ pharmacological pathways, food‑development landscape, pain‑points and upgrading strategies. The objective is to bridge ethnopharmacological heritage, modern experimental evidence and industrial reality, helping researchers and enterprises identify research gaps and feasible development directions.

2. Botanical Background and Major Bioactive Constituents of Cistanche deserticola

2.1 Botanical comparison between Cistanche deserticola and Cistanche tubulosa

Genus Cistanche under Orobanchaceae includes eight native Chinese species, among which desert cistanche (C. deserticola) and tubular cistanche (C. tubulosa) are the two official botanical sources documented in Chinese Pharmacopoeia. These two species differ remarkably in host selection, morphological traits, tissue anatomy and geographical distribution.

Cistanche deserticola parasitizes roots of Haloxylon ammodendron and Haloxylon persicum. Its succulent stem appears stout and short, with yellow‑brown to gray‑brown surface densely covered by scale leaves; stem tissue lacks stomata and exhibits star‑shaped pith structure. Natural distribution spreads across western Inner Mongolia, Ningxia, Gansu, Qinghai and partial Xinjiang, growing within altitudes ranging from 225 m to 1 150 m in desert dune ecosystems.

By contrast, Cistanche tubulosa chooses Tamarix shrubs as host plants. Morphologically it develops slender, elongated succulent stems with dark‑brown to black‑brown epidermis and sparse scales; stem tissues contain stomata but no pith. Wild and cultivated resources concentrate around the Taklamakan Desert in southern Xinjiang.

Crucially, only Cistanche deserticola (desert variety) obtained Food‑Medicine Homology qualification in 2023. Cistanche tubulosa is still restricted to pharmaceutical usage and cannot be applied in ordinary food production. Morphological resemblance creates risks of species adulteration during raw‑material procurement.

2.2 Primary bioactive compounds and quality‑influencing variables

Over 130 secondary metabolites have been isolated so far from Cistanche genus plants. Four major chemical families dominate biological activities: phenylethanoid glycosides (PhGs), iridoids, lignans and polysaccharides. Within PhGs, echinacoside (ECH) and acteoside (verbascoside, ACT) serve as mandatory quality‑control markers specified by Chinese Pharmacopoeia. Their contents directly determine herbal‑material grade.

Compound distribution displays obvious tissue specificity. Bioactive‑compound concentrations reach highest level within lower segments of succulent stems and gradually decline toward upper stem and flowering parts. Lignified old stems and inflorescence tissues show drastically different chemical profiles and are not recommended for food‑grade raw‑material sourcing.

Multiple external and agronomic factors shape final ingredient abundance: geographical origin, host‑plant health status, growing climate, harvesting season and post‑harvest processing procedures all cause significant content fluctuation. Improper drying or long‑term ambient‑temperature storage accelerates enzymatic degradation of PhGs, lowering commercial value. Representative major compounds and their reported bio‑functions are summarized as follows.

Phenylethanoid glycosides (PhGs)

Echinacoside: neuroprotection, hepatoprotection, anti‑inflammation, myocardial‑damage alleviation, modulates reproductive steroid synthesis

Acteoside (verbascoside): anti‑oxidation, neuro‑synaptic preservation, anti‑inflammatory response

Salidroside: anti‑fatigue, anti‑hypoxia, anti‑oxidative stress

2'‑Acetylacteoside: intestinal‑smooth‑muscle relaxation, osteoclast‑formation suppression, neuro‑cell‑protective effects

Isoacteoside: mitigation of renal‑injury progression

Cistanoside A: osteogenic promotion, dopaminergic‑neuron protection

Tubuloside A / Tubuloside B: anti‑aging, hepatoprotection and anti‑inflammatory properties

Iridoid compounds: 6‑deoxycatalpol, 8‑epiloganic acid, geniposidic acid, contributing anti‑oxidant, anti‑inflammatory and mild antimicrobial capacity.

Lignans: pinoresinol, liriodendrin, eucommin A, associated with myocardial‑cell protection and liver‑tissue damage mitigation.

Polysaccharide fractions: complex carbohydrate mixtures without fixed single molecular formula. Polysaccharides regulate gut‑microbiota composition, mediate immune‑cell responses, exert anti‑oxidant, anti‑aging and liver‑protective outcomes. Polysaccharide‑mediated gut‑brain‑axis modulation attracts rising research interest for cognitive‑function improvement.
 

3. Multidimensional Pharmacological Functions and Mechanism Interpretation

Modern pharmacological investigations uncover multi‑target, multi‑pathway regulatory characteristics of Cistanche deserticola extracts and purified monomers. Pre‑clinical cell‑culture and animal‑model experiments constitute most existing evidence; limited small‑sample human clinical trials supply preliminary supporting data.

3.1 Neuroprotective effects and cognitive‑improvement mechanisms

Accumulated pre‑clinical data supports neuroprotective potential targeting Alzheimer's disease (AD) and other neurodegenerative pathologies. Core working mechanisms include antioxidant‑stress defense, neuroinflammation inhibition, Aβ‑peptide deposition retardation, Tau‑protein hyper‑phosphorylation suppression, synaptic‑plasticity maintenance, neuronal‑apoptosis inhibition and intracellular calcium‑homeostasis stabilization.

First, PhGs components strengthen endogenous anti‑oxidant enzymatic systems: elevating SOD and GSH‑Px activity while reducing MDA and excess reactive‑oxygen‑species (ROS) levels inside nervous tissue. Second, echinacoside suppresses over‑activation of microglia cells, down‑regulating Iba‑1 biomarker expression and restraining NF‑κB‑driven neuroinflammatory cascades. Third, active ingredients ameliorate cholinergic‑system dysfunction: lowering acetylcholinesterase (AChE) activity, preserving acetylcholine concentration, boosting hippocampal dopamine content and up‑regulating synaptic‑related proteins SYN and PSD‑95, therefore counteracting synapse loss. Fourth, mitochondrial‑dependent apoptotic signaling gets modulated: raising anti‑apoptotic Bcl‑2 expression, decreasing Bax/Bcl‑2 ratio and suppressing Caspase‑3 activation to limit neuron programmed death.

Furthermore, cistanche polysaccharides reshape gut‑microbiome community structure, enriching Bacteroidetes abundance and restoring gut‑brain‑axis balance, indirectly benefiting learning‑memory capacity. Several small‑scale human pilot‑studies demonstrated that cistanche‑glycoside‑based interventions stabilized cognitive performance among AD participants. Combined cistanche‑ginkgo‑biloba extract supplementation improved Montreal Cognitive Assessment (MoCA) scores among middle‑aged and elderly subjects with mild cognitive decline after 12‑week continuous intake. Preliminary observations also hint benefits for locomotive‑syndrome gait parameters and depressive‑mood relief in Yang‑deficiency‑constitution populations.

3.2 Cardioprotective pharmacological pathways

Cistanche deserticola and its signature constituent echinacoside exert comprehensive myocardial‑protective activity via lipid‑profile adjustment, anti‑inflammation, endothelial‑function improvement, mitochondrial‑quality control and multiple programmed‑cell‑death‑pattern regulation (apoptosis, pyroptosis and ferroptosis).

In lipid‑metabolism regulation, extracts decrease serum total cholesterol, triglyceride and LDL‑cholesterol concentrations and increase HDL‑cholesterol proportion. Diabetic‑cardiomyopathy animal‑model research indicates modulation over PPAR‑α / M‑CPT‑1 signaling axis and CD36‑GLUT‑4 protein expression, correcting disordered cardiac lipid deposition.

For vascular‑endothelial protection, active compounds trigger NO‑mediated vasorelaxation and block NF‑κB‑inflammatory‑pathway transduction, mitigating ischemia‑provoked myocardial infarction scope. Echinacoside elevates SIRT1‑FOXO3a‑MnSOD signaling activity, counteracts mitochondrial ROS burst and reverses pathological myocardial remodeling within heart‑failure rodent models.

Recent mechanistic progress reveals its capacity to antagonize doxorubicin‑triggered cardiomyocyte ferroptosis: increasing GPX4 expression, lowering PTGS2 level and restraining lipid‑peroxide accumulation. It also inhibits NADPH‑ROS‑endoplasmic‑reticulum‑stress cascades to reduce myocardial pyroptosis. Meanwhile, it alleviates angiotensin‑II‑induced cardiac fibrosis by tuning SIRT1‑IL‑11 regulatory network and modifying serum myocardial‑injury biomarkers (LDH, CK‑MB, ANP, BNP, cTnT).
 

3.3 Reproductive‑system protective activities

Traditional TCM texts emphasize cistanche's "tonify kidney‑yang, replenish essence" indications for reproductive‑health support. Contemporary studies illustrate effects centered on hypothalamic‑pituitary‑gonadal‑axis regulation, steroid‑hormone‑synthesis‑enzyme modulation and lipid‑metabolite‑network reconstruction.

Echinacoside and total cistanche glycosides up‑regulate key steroidogenic enzymes including StAR, CYP11A1 and 3β‑HSD inside testicular tissue, alleviating toxicant‑caused testicular damage and improving sperm‑quality indicators. At hypothalamus level, PhGs modulate Kisspeptin‑1 / GPR54 / SIRT1 / SOCS‑3 molecular circuit to re‑balance gonadotropin‑releasing‑hormone output, subsequently adjusting LH and testosterone secretion. Molecular‑interaction research suggests echinacoside can bind androgen‑receptor pockets and modify receptor nuclear‑translocation behavior, interfering with sex‑hormone negative‑feedback loops. Amino‑acid constituents additionally support ovarian‑hormone‑secretion equilibrium.

3.4 Bone‑metabolism‑regulating function against osteoporosis

Osteoporosis pathology originates from disrupted bone‑remodeling equilibrium: over‑activated osteoclast bone‑resorption surpasses osteoblast bone‑formation. Cistanche ingredients coordinate multiple signaling axes (RANKL‑RANK‑OPG, Wnt/β‑catenin, BMP‑Smad and MAPK pathways) to restore bone homeostasis.

PhGs suppress RANKL‑triggered osteoclast differentiation. They down‑regulate RANKL and phosphorylated β‑catenin expression, whereas elevating OPG, BMP‑2 and osteocalcin (OCN) abundance, accelerating calcium deposition and new‑bone matrix formation. Certain monomer molecules like cistanoside‑A depress JNK‑MAPK‑pathway over‑activation to curb osteoclast‑specific‑gene transcription. Partial compounds display phyto‑estrogen‑like bioactivity, defending osteoblasts against apoptosis via P53‑dependent routes.

Intestinal‑microbiota intervention represents another innovative mechanism. Cistanche polysaccharides modify gut‑microbiota‑short‑chain‑fatty‑acid‑Th17/Treg immune‑cell axis, dampening excessive osteoclast activation from inflammatory‑immune disturbance. A six‑month clinical observation on primary‑osteoporosis patients demonstrated oral cistanche‑decoction improved bone‑mineral‑density markers and serum bone‑turnover biochemical indicators compared with calcium‑supplement control groups.

3.5 Intestinal‑tract protective effects

Cistanche deserticola acts on gastrointestinal health through three major dimensions: promoting intestinal‑transit function for senile constipation, easing inflammatory‑bowel pathological damage and supporting epithelial‑mucosa repair.

For constipation‑relief, cistanche decoction modulates SCF/C‑kit pacemaker‑cell signaling: elevating connexin‑43 expression and suppressing aquaporin‑3 expression inside colon tissue, restoring slowed intestinal peristalsis in aged‑constipation animal‑models. Cistanche polysaccharides relieve irritable‑bowel‑syndrome‑related symptoms by restraining NGF‑TRKA over‑signaling.

Regarding intestinal‑inflammatory injury, total glycosides inhibit mTOR‑TGF‑β protein over‑expression in spleen tissue to mitigate inflammatory‑bowel‑disease progression. Extracts protect gastrointestinal mucosa: acteoside exhibits anti‑ulcer capacity in pylorus‑ligature injury‑models, while echinacoside stimulates MODE‑K intestinal‑epithelial‑cell proliferation and anti‑apoptosis by enhancing TGF‑β1 secretion. Oral water‑extract also alleviates Helicobacter‑pylori‑linked intestinal hyper‑proliferation in pre‑clinical settings.

3.6 Bidirectional immunomodulatory performance

Cistanche bio‑substances produce dual‑direction immune‑regulatory outputs: boosting innate‑and‑adaptive immune competence while simultaneously restraining excessive pro‑inflammatory bursts.

Polysaccharide fractions enhance macrophage phagocytic‑activity, drive lymphocyte proliferation and promote dendritic‑cell maturation for antigen‑presentation function. They expand CD4‑positive T‑cell sub‑populations and raise CD4/CD8 ratio. On the anti‑inflammatory side, PhGs interfere with MyD88‑TAK1‑NF‑κB‑MAPK signal cascades and cut down TNF‑α, IL‑6 and IL‑1β pro‑inflammatory‑cytokine release. This dual characteristic distinguishes it from simple single‑direction immune‑stimulant agents. Small‑sample human intervention trials on elderly volunteers verified that cistanche‑extract supplementation elevated NK‑cell activity and optimized peripheral‑blood T‑lymphocyte‑subset distribution after 12‑week intake.

3.7 Summary of human clinical‑trial evidence

Published human‑subject research remains limited to small‑sample, single‑center pilot‑observations, most lacking large‑scale multi‑center randomized controlled‑trial validation. Reported intervention scenarios cover Alzheimer‑disease auxiliary treatment, post‑stroke cognitive‑impairment, chronic‑fatigue‑syndrome, primary osteoporosis, Yang‑deficiency‑type depression, hemodialysis‑patient auxiliary intervention and androgen‑related alopecia adjuvant observation. Existing clinical data delivers promising preliminary signals, but evidence grade stays moderate to low; further high‑quality clinical investigations are urgently required before making definitive therapeutic claims for food‑product labeling.

Important note for industrial application: according to global food‑regulatory rules, these pre‑clinical and preliminary clinical findings cannot be directly translated into disease‑treatment statements on food‑product packaging. Functional‑claim labeling must comply with local food‑law requirements in target‑sales jurisdictions.

4. Global Industrial and Food‑Development Landscape

4.1 Domestic Chinese market status after Food‑Medicine‑Homology approval

Before 2023, cistanche products were divided into crude‑drug material, TCM‑decoction‑pieces, patent‑Chinese‑medicines and national‑approved health‑care‑foods. Following Food‑Medicine‑Homology listing of Cistanche deserticola, ordinary‑food‑product development formally opened.

4.1.1 Health‑care‑food (nutraceutical) product landscape

Searching public Chinese health‑food registration database up to mid‑2025 returns 71 cistanche‑related health‑food records. Main dosage forms include tablets, wine formulations, capsules, granules, oral liquids and substitute‑tea bags. Dominant officially‑allowed functional claims are enhancing immunity and alleviating physical‑fatigue. Popular compatible herbal‑ingredient combinations include Panax ginseng, Lycium barbarum, Cuscuta chinensis, Ziziphus jujuba, Epimedium and Panax quinquefolius. Different herbal matches correspond to sub‑product positioning: anti‑aging formulas often pair cistanche with ginseng, wolfberry and dodder seed; fatigue‑relieving immunity‑boosting products frequently blend wolfberry, epimedium and American‑ginseng.

4.1.2 Ordinary‑food development progress

Presently, over 80 % of domestic cistanche commercial goods still belong to primary agricultural commodities: simply sliced, sun‑dried raw‑herb without deep processing. Innovative refined‑food categories have emerged but remain relatively scarce, covering herbal beverages, concentrated original‑pulp, functional tablets, fermented drinks, substitute‑tea, coffee, yoghurt, gummy candy and sports‑nutrition‑supplement powders. Representative formula‑cases combine cistanche with Lycium barbarum, Polygonatum sibiricum, Panax ginseng, Maca and mulberry‑fruit. Manufacturing‑processes applied include ultra‑low‑temperature wall‑breaking, low‑temperature high‑pressure concentration, cold‑extraction, membrane‑concentration enrichment and low‑temperature slow‑drying.

Special‑dietary‑food examples incorporate cistanche into sports‑nutrition‑formulas mixed with whey‑protein isolate, L‑carnitine, astaxanthin and other plant‑botanical ingredients. Nevertheless, most innovative‑food products remain at small‑batch trial‑production stage rather than mass‑market mainstream retail goods.

4.2 International market development situation

Global market‑research reports indicate the Asia‑Pacific region accounts for 47.2 % of worldwide cistanche‑product market revenue share, with China acting as core production‑and‑consumption hub. In overseas jurisdictions, regulatory‑approval obstacles retard food‑ingredient authorization. European Food‑Safety‑Authority (EFSA) once assessed cistanche‑stem water‑extract as potential novel‑food raw‑material; the expert‑panel concluded available safety‑evidence was insufficient for formal novel‑food‑recognition. In Japan and United‑States public food‑ingredient databases, no official food‑ingredient registration records for Cistanche deserticola can be retrieved.

Cross‑border‑export constraints also originate from wild‑plant‑protection‑related trade‑administrative measures. On Amazon and North‑American e‑commerce channels, consumer‑available cistanche goods are nearly all dietary‑supplement‑style capsules, tablets and powdered extracts. Compound‑formula products are rare. Common overseas‑market compound supplements combine cistanche with Tribulus terrestris, Eurycoma longifolia, Withania somnifera and ginseng, mostly marketed for physical‑vitality support. These goods are sold under "dietary‑supplement" classification instead of conventional‑food category.

5. Core Industrial Challenges for Food‑Oriented Development

Three major challenge clusters constrain transformation from medicinal‑herb to large‑scale food‑industry resource: resource‑sustainability risks, fragmented quality‑control‑standard‑systems and market‑operation bottlenecks.

5.1 Resource‑sustainability challenges of parasitic cultivation

Cistanche deserticola is an obligate holoparasite. Natural seed‑germination and host‑haustorium‑formation success‑rate stays intrinsically low, demanding specific chemical‑signal stimuli released from host‑plant root exudates to trigger developmental transition. Even with manual pre‑treatment including pericarp‑stripping, cold‑stratification and variable‑temperature incubation, parasitic‑establishment efficiency remains limited.

Desert‑zone host‑plant Haloxylon ammodendron requires irrigation within water‑scarce arid environments. Wild‑animal browsing (camel and rodent feeding damage) impairs host‑plant survival and indirectly reduces cistanche yield. Production zones are geographically remote desert areas, facing insufficient agricultural‑technical‑extension coverage and shortage of interdisciplinary industrial‑talent. Traditional experience‑based "mentor‑apprentice" knowledge‑spreading mode prevails; standardized large‑scale agronomic‑management implementation encounters resistance.

Although research progress has proven exogenous‑hormone (gibberellin, fluridone) and host‑root‑extract treatments improve seed‑germination rate; mechanical integrated‑inoculation plus drip‑irrigation agronomic‑techniques enhance field output. The whole industrial‑chain still suffers high‑initial‑investment, unstable survival‑rate problems. Present production capacity cannot fully satisfy potential future food‑mass‑market demand.

5.2 Quality‑control and standard‑system deficiency

Quality fluctuation represents prominent pain‑points. Multiple factors drive raw‑material quality inconsistency: botanical‑species confusion, variable‑growing‑conditions, non‑standard‑harvest‑timing and informal manual‑processing by scattered farmers.

First, species‑adulteration risk: several Cistanche species possess highly‑similar morphological appearances. Visual morphological‑identification cannot reliably differentiate species. DNA‑barcode molecular‑identification‑technology exists but sees low penetration rate in grassroots‑circulation‑links, enabling mixing of non‑qualified related‑species into commercial‑material streams.

Second, lack of unified full‑chain‑standards. Chinese‑Pharmacopoeia‑standards target crude‑drug‑herb and decoction‑pieces only. Unified mandatory specifications for food‑grade extracts, food‑intermediate‑materials (limits for heavy‑metals, pesticide‑residues and minimum‑active‑ingredient‑threshold) are absent. Existing national‑standard GB/T 41628‑2022 is cultivation‑technical‑specification rather than finished‑product‑quality‑criteria. Regional local‑standards from Inner‑Mongolia, Gansu and Qinghai set different numerical thresholds for total‑echinacoside‑plus‑acteoside content (0.3 % vs 0.5 %), creating inconsistency across provinces.

Third, detection‑technology‑implementation gap. High‑performance‑liquid‑chromatography (HPLC) instruments are not universally accessible in primary‑production‑counties. Rapid‑field‑detection‑technologies such as near‑infrared‑spectroscopy still require further‑optimized calibration‑models for on‑site large‑batch screening. Post‑harvest primary‑processing is decentralized among individual farmers. Improper drying‑and‑storage‑operations induce enzymatic browning, mildew and active‑ingredient loss.

Emerging improved‑processing‑technologies including fresh‑processing immediately after harvesting, radio‑frequency vacuum‑drying, ultra‑high‑pressure‑assisted‑drying and freeze‑infrared‑hybrid‑drying demonstrate advantages in preserving PhGs and polysaccharide contents, yet large‑scale industrial adoption remains limited.

5.3 Market‑development and commercial‑operation bottlenecks

Market‑level obstacles divide into enterprise‑capacity constraints, serious‑product‑homogenization and consumer‑cognition‑bias.

Most cistanche‑related enterprises are small‑to‑medium‑sized local firms with limited capital‑reserves. They lack resources to construct deep‑processing production‑lines and invest in brand‑building and consumer‑science‑popularization campaigns. Recruiting food‑R&D and marketing‑specialists becomes difficult under remote‑region‑economic‑conditions, forming vicious‑cycle: low‑technical‑level → low‑added‑value‑goods → poor‑profitability → insufficient‑R&D‑input.

Product‑homogenization is severe. More than 80 % market offerings belong to primary‑processed dried‑slices. Food‑product innovation remains insufficient. Marketing‑narratives excessively focus on historical "kidney‑yang‑tonifying" traditional‑impression. Formulas tend to repeat existing tonic‑herb combinations. Few products are developed oriented toward women consumers, youth‑groups, intestinal‑comfort and anti‑oxidant‑daily‑nutrition‑demands. Product‑formats poorly match modern‑lifestyle‑scenarios such as office‑snacks, ready‑to‑drink‑beverages and portable‑sports‑nutrition‑supplements.

Public‑cognition deviation restricts audience‑expansion: general‑consumer perception overly associates cistanche exclusively with male‑specific tonic‑use, ignoring multi‑faceted health‑potential for immune‑balance, intestinal‑wellbeing and anti‑oxidative‑maintenance suitable for broader‑population‑groups. Additionally, regulatory‑limitations forbid ordinary‑food‑products to print explicit‑functional‑effect‑claims on‑packaging, increasing difficulty for value‑communication toward consumers.

6. Upgrading Strategies and Future Industrial Perspectives

Counter‑measures are proposed from three dimensions: strengthening resource‑sustainability‑technology‑support, constructing whole‑industrial‑chain standardized‑quality‑management‑system and promoting market‑value‑release through innovation‑driven‑industrial‑upgrading.

6.1 Reinforce sustainable‑cultivation technical‑support‑system

Multi‑disciplinary joint‑research should deepen parasitic‑biology‑mechanism exploration. R&D priorities include screening high‑germination‑rate germplasm‑resources, developing targeted‑biostimulant‑agents to boost parasitic‑attachment‑ratio. Promote mechanized‑field‑operations covering forest‑site‑selection, ditching, seed‑inoculation, harvesting and plant‑protection‑work. Deploy drone‑remote‑sensing monitoring systems for host‑forest‑ecosystem‑management and integrated‑pest‑and‑disease‑prevention‑and‑control.

Government‑led public‑technical‑service‑stations should be built within major‑producing‑regions, delivering systematic‑agronomic‑training for planters. Encourage higher‑education‑institutions to cultivate compound‑talents covering desert‑botany‑cultivation, food‑deep‑processing‑engineering and quality‑inspection‑expertise, breaking dual‑bottlenecks of technical‑diffusion‑barriers and talent‑shortage.

6.2 Establish complete full‑chain quality‑control‑standard‑architecture

National‑level coordination should launch unified‑standard‑setting work covering food‑grade‑cistanche crude‑material, extracts and terminal‑food‑products. Harmonize active‑ingredient‑minimum‑content‑thresholds, heavy‑metal and pesticide‑residue‑safety‑limits to eliminate contradictions between different‑provincial‑local‑standards.

Policy‑oriented financial‑support may popularize essential‑analytical‑equipment at grassroots‑production‑bases. Accelerate development and validation of portable‑rapid‑detection‑kits (immunochromatographic‑test‑strips etc.) for fast‑batch‑screening. Scale‑up demonstration‑bases implementing fresh‑post‑harvest‑processing‑specifications, foster enterprise‑plus‑farmers‑co‑operation‑mode to realize standardized‑primary‑processing on‑site, minimizing bio‑active‑component degradation. Reinforce market‑supervision and traceability‑construction to suppress adulteration‑and‑counterfeiting‑phenomenon.

6.3 Drive market‑innovation and unlock industrial‑value potential

Policy incentives may guide capital‑resources to integrate scattered‑small‑enterprises and nurture leading‑industrial‑corporations capable of undertaking high‑level‑R&D and brand‑operation. Strengthen university‑enterprise‑co‑innovation‑projects. R&D directions should expand beyond single‑traditional‑male‑tonic‑positioning. Develop innovative‑food‑products targeting intestinal‑health, bone‑health‑care, anti‑fatigue‑daily‑nutrition and middle‑aged‑women‑sub‑groups. Apply modern‑food‑technologies such as micro‑encapsulation and microbial‑fermentation to enhance ingredient‑bio‑availability and product‑added‑value.

Carry out objective‑consumer‑science‑popularization work via multi‑channel online‑and‑off‑line communication, correcting one‑sided‑stereotyped‑market‑perception. Design product‑formats fitting contemporary‑everyday‑consumption‑scenarios: ready‑to‑drink‑bottled‑beverages, portable‑solid‑drinks, nutritional‑gummies and sports‑nutrition‑portions. Meanwhile, actively engage in international‑safety‑assessment‑submission procedures, leveraging cross‑border‑e‑commerce and global‑exhibition‑platforms to advance overseas‑market‑exploration. Realize comprehensive transformation from low‑price‑raw‑material‑export toward high‑value‑branded‑nutraceutical‑commodity output.

7. Conclusion

Cistanche deserticola ("desert ginseng") represents a precious desert‑origin Food‑Medicine‑Homology botanical‑resource in China. Its rich phenylethanoid‑glycosides, polysaccharides and other bio‑substances deliver multi‑organ protective‑bioactivities validated by abundant pre‑clinical‑research and preliminary‑human‑observations. The 2023 Food‑Medicine‑Homology regulatory‑update unlocked huge prospects for functional‑food‑industrial‑development. Nevertheless, sustainable‑parasitic‑cultivation restrictions, imperfect‑quality‑standard‑systems and market‑homogenization‑pain‑points still block high‑quality‑industrial‑growth.

Future progress demands joint‑efforts across scientific‑research‑institutes, government‑regulators and industrial‑enterprises. Breakthroughs should focus on improving parasitic‑cultivation‑efficiency, completing unified full‑chain‑quality‑control‑framework, developing innovative‑consumer‑oriented‑food‑products matching diverse‑population‑demands and conducting high‑quality‑large‑sample‑human‑clinical‑trials to solidify evidence‑base. By converting unique desert‑biological‑resource‑advantages into real‑world‑industrial‑competitiveness, Cistanche deserticola can better serve domestic‑and‑global‑preventive‑nutrition‑markets.

References

[1] Xu X Y, Zhang S J, Li X, et al. Functional properties of Roucongrong (Cistanches Herba) and its current status and challenges in food development[J]. Journal of Food and Medicine Homology, 2025, 1(9): 32‑50.

[2] Zhang S G, Ma Y W, Chen J, et al. Chemical composition, pharmacological effects, and parasitic mechanisms of Cistanche deserticola: An update[J]. Phytomedicine, 2024, 132:155808.

[3] Cheng N, Wang H, Hao H F, et al. Research progress on polysaccharide components of Cistanche deserticola as potential pharmaceutical agents[J]. European Journal of Medicinal Chemistry, 2023, 245:114892.

[4] Fu Z F, Han L F, Zhang P, et al. Cistanche polysaccharides enhance echinacoside absorption in vivo and affect the gut microbiota[J]. International Journal of Biological Macromolecules, 2020,149:732‑740.

[5] Gao Y, Li B, Liu H, et al. Cistanche deserticola polysaccharides alleviate cognitive decline in aging model mice by restoring the gut microbiota‑brain axis[J]. Aging, 2021,13(11):15320‑15335.

[6] Kan J T, Cheng J R, Hu C, et al. A botanical product containing Cistanche and Ginkgo Extracts potentially improves chronic fatigue syndrome symptoms in adults: A randomized, double‑blind, and placebo‑controlled study[J]. Frontiers in Nutrition, 2021, 8:658630.

[7] Chen L, Liu X, Zheng J H, et al. A randomized, double‑blind, placebo‑controlled study of Cistanche tubulosa and Ginkgo biloba extracts for the improvement of cognitive function in middle‑aged and elderly people[J]. Phytotherapy Research, 2024,38(8):4272‑4285.

[8] Global Cistanche deserticola market size, share, and trends analysis report‑industry overview and forecast to 2032[R]. Data Bridge Market Research,2025.